growth track reduc tp mtm multipl
make minor earn downgrad ebit result retain
outperform rate reduc target price
mtm multipl continu forecast return mid-high singl digit structur
growth support hygien launch corn inocul uptak
share gain energy/household acknowledg fall oil price may
encourag switch enzym chemic base product though still believ
novozym grow core busi growth
new product pipelin believ market gain comfort busi
resili share continu outperform european chemic
valuat risk valu novozym averag
price-to-earnings multipl ev/ebitda multipl
dcf wacc estim novozym
structur increas growth rate prove prove
resili european chemic econom downturn
scenario given defens end market new market penetr
opportun risk invest case lower oil price impact market
valuat metric
price month
price rel chart measur perform
omxc close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novozym a/ denmark-bas biotechnolog compani
engag product sale industri enzym
busi consist two segment enzym busi segment
price jan rate outperform target price analyst mathew hampshire-waugh
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
return peak oil would gener organ growth
could justifi novozym rerat toward histor pe premium
return trough oil would gener organ growth could
justifi novozym derat toward low end histor pe
trade
price rel chart measur perform omxc
close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
downgrad forecast ebit averag forecast period updat
macro assumpt earn chang seen
figur credit suiss earn forecast chang novozym
novozym target price averag
peer multipl base
dcf valuat novozym
less increase/add decreas wc
free cash-flow firm fcff
cumul factor period
discount factor start first forecast period
share
peer multipl valuat pe ev/ebitda
highlight month forward consensu ev/ebitda basi novozym
trade discount peer discount year averag
month forward consensu price-to-earnings novozym trade discount peer
discount year histor averag premium
rel
compani mention price
